Those who qualify may receive:
There is no obligation, so see if you may qualify now.
RSV infects the lungs, nose, throat and breathing passages, and causes common cold-like symptoms. Both RSV infection and pneumococcal disease peak during the winter season.
RSV can infect people of all ages including older adults, who may develop serious complications leading to hospitalization.
What to expect
The investigational vaccine will be studied alongside an approved 20-valent pneumococcal conjugate vaccine (PCV20). Pneumococcal infections can cause problems such as pneumonia and meningitis. Like RSV, pneumonia can severely affect older adults.
If you choose to take part in the study, you will be randomly assigned to either Group 1 or Group 2.
Our team will contact you to verify your eligiblity and answer any questions you may have.